688062 迈威生物-U
已收盘 05-29 15:00:01
资讯
新帖
简况
股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%
证券之星 · 05-29 01:00
股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%
每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%
证券之星 · 05-24
每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%
迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%
证券之星 · 05-21
迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%
迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据
智通财经网 · 05-21
迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据
迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准
美股速递 · 05-20
迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准
迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准
智通财经 · 05-20
迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准
5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股
证券之星 · 05-11
5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股
港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可
智通财经网 · 05-11
港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
美股速递 · 05-08
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
智通财经网 · 05-08
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元
美股速递 · 05-06
迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元
迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具
智通财经 · 05-06
迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具
迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市
新浪港股 · 04-30
迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市
港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布
智通财经 · 04-30
港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布
迈威生物（688062）2026年一季报简析：营收上升亏损收窄
证券之星 · 04-30
迈威生物（688062）2026年一季报简析：营收上升亏损收窄
迈威生物2026年第一季度净亏损2.42亿元
北京商报 · 04-28
迈威生物2026年第一季度净亏损2.42亿元
深港通下的港股通标的证券名单调入迈威生物-B，今日起生效
老虎资讯综合 · 04-28
深港通下的港股通标的证券名单调入迈威生物-B，今日起生效
【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍
金吾财讯 · 04-28
【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍
上交所：将迈威生物-B(02493)调入沪港通下的港股通标的
智通财经 · 04-27
上交所：将迈威生物-B(02493)调入沪港通下的港股通标的
每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元
证券之星 · 04-26
每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":30.4,"timestamp":1780038001000,"preClose":30.59,"halted":0,"volume":12455469,"delay":0,"changeRate":-0.0062,"floatShares":204000000,"shares":447000000,"eps":-2.0584,"marketStatus":"已收盘","change":-0.19,"latestTime":"05-29 15:00:01","open":30.8,"high":31.1,"low":28.98,"amount":375000000,"amplitude":0.0693,"askPrice":30.4,"askSize":126,"bidPrice":30.39,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-2.0584,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":30.59,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":33.65,"lowLimit":27.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446730200,"isCdr":false,"pbRate":127.14,"roa":"--","roe":"--","epsLYR":-2.43,"committee":-0.306878,"marketValue":13581000000,"turnoverRate":0.061,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-01。","afterMarket":{"amount":0,"volume":0,"close":30.4,"buyVolume":700,"sellVolume":0,"time":1780040038866,"indexStatus":"已收盘 05-29 15:30:00","preClose":30.59},"hkstockBrief":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":22.78,"timestamp":1780042104954,"preClose":22.82,"halted":0,"volume":664800,"delay":0,"premium":"-35.33"},"floatMarketCap":6207000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2639690317","title":"股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639690317?lang=zh_cn&edition=full","pubTime":"2026-05-29 01:00","pubTimestamp":1779987637,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，迈威生物报收于30.59元，下跌4.73%，换手率3.82%，成交量7.79万手，成交额2.42亿元。当日关注点来自交易信息汇总：迈威生物股价连续3日下跌，当日主力资金净流出3344.38万元，占总成交额13.82%。交易信息汇总股价提醒5月28日迈威生物收盘报30.59元，跌4.73%，当日成交779.41万元。该股已连续3日下跌，当年累计跌幅21.26%。前10个交易日主力资金累计净流出5861.72万元，股价累计下跌13.61%；融资余额累计增加852.75万元，融券余量累计增加1.71万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637782093","title":"每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637782093","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637782093?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:48","pubTimestamp":1779558494,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，迈威生物报收于33.31元，较上周的34.34元下跌3.0%。本周，迈威生物5月22日盘中最高价报35.35元。公司公告汇总：9MW2821联合特瑞普利单抗在尿路上皮癌中整体人群ORR达83.0%。迈威生物自主研发的靶向Nectin-4 ADC药物9MW2821在2026年ASCO年会上以口头报告和壁报形式展示最新临床数据。9MW2821联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II期研究显示，整体人群客观缓解率为83.0%，经确认ORR为74.5%，完全缓解率12.8%，中位无进展生存期12.9个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637051332","title":"迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637051332?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:38","pubTimestamp":1779374294,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，迈威生物报收于33.48元，较前一交易日上涨1.09%，最新总市值为149.57亿元。该股当日开盘33.25元，最高35.07元，最低33.25元，成交额达3.61亿元，换手率为5.18%。近日，迈威生物发布自愿披露公告，宣布其自主研发的靶向Nectin-4 ADC药物9MW2821在2026年美国临床肿瘤学会年会上，将以口头报告和壁报形式展示最新临床数据。两项研究均未发现新的安全性信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389898","title":"迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389898","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389898?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:17","pubTimestamp":1779355058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司将在2026年5月29日-6 月2日于芝加哥举行的2026年美国临床肿瘤学会年会中，以口头报告形式公布靶向Nectin-4ADC创新药9MW2821 联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II 期临床研究数据，以壁报形式公布9MW2821联合特瑞普利单抗用于围手术期肌层浸润性膀胱癌的II期临床研究数据。9MW2821给药后，可与肿瘤细胞表面的Nectin-4结合并进入细胞，通过酶解作用，定向释放细胞毒素，从而实现对肿瘤的精准杀伤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","02493","BK1161","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163729672","title":"迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163729672","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163729672?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:46","pubTimestamp":1779288374,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司宣布，其核心产品迈卫健®注射液新增适应症补充申请，已正式获得国家药品监督管理局的批准。\n此次获批意味着迈卫健®注射液的临床应用范围得到进一步拓宽，将为更广泛的适应症患者群体提供新的治疗选择。作为公司重要的在研及商业化产品，此次监管进展有望强化其市场地位，并为未来的商业化表现注入新的增长动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636121668","title":"迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636121668","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636121668?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:27","pubTimestamp":1779265627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司全资子公司江苏泰康生物医药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，地舒单抗注射液增加实体肿瘤骨转移和多发性骨髓瘤适应症的补充申请获得国家药品监督管理局批准。公告显示，迈卫健主要竞争优势在于：1)作为国内第一梯队上市的安加维生物类似药，先发优势明显;2)展现了良好的治疗效果，被多个专家共识或治疗指南推荐。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","BK1161","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409827","title":"5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409827?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488118,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日迈威生物涨5.80%，收盘报37.2元，换手率6.99%，成交量14.28万手，成交额5.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7862，较上一交易日下跌2.29%，近一年上涨13.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493","688062","000808.SH","BK0239","163118"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634472914","title":"港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2634472914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634472914?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:57","pubTimestamp":1778479078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午后涨近5%，截至发稿，涨3.54%，报27.52港元，成交额3326.31万港元。消息面上，迈威生物宣布，其自主研发的抗体创新药9MW5211的临床试验申请正式获得美国食品药品监督管理局的许可，可针对炎症性肠病开展临床研究。其用于IBD和多发性硬化等多个适应症的临床试验申请已获国家药品监督管理局受理。9MW5211在其靶点上是全球首款进入临床阶段的候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","06978","VXUS","02493","BK4588","159992","BK1161","LABU","BK4585","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154828404","title":"迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1154828404","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154828404?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:55","pubTimestamp":1778252116,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其研发的9MW5211注射液用于治疗炎症性肠病的临床试验申请，已获得美国食品药品监督管理局（FDA）的正式批准。这一进展标志着该药物在海外临床开发方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432532","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432532","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432532?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:15","pubTimestamp":1778235339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，，9MW5211注射液用于炎症性肠病适应症的临床试验申请正式获得FDA许可，同时，其用于IBD和多发性硬化等多个适应症的临床试验申请已获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","02493","BK4588","BK1161","LABU","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134132557","title":"迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134132557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134132557?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:36","pubTimestamp":1778078171,"startTime":"0","endTime":"0","summary":"迈威生物宣布，公司计划向中国银行间市场交易商协会提交申请，拟注册发行定向债务融资工具。本次发行的总规模将不超过人民币10亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131510","title":"迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131510?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:09","pubTimestamp":1778076591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，为进一步优化债务结构，拓宽公司融资渠道，降低公司财务成本，根据公司战略发展规划及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过10亿元(含10亿元)的定向债务融资工具。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631702570","title":"迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631702570","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631702570?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:31","pubTimestamp":1777519860,"startTime":"0","endTime":"0","summary":" 迈威生物-B最高涨超23%，触及31.46港元，创上市新高。截至发稿，涨7.22%，报27.32港元，成交额1.84亿港元。自成立以来，公司已推动4款产品获批上市，实现4款创新品种的对外授权。 值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-30/doc-inhwfyeh7154434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631357717","title":"港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2631357717","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631357717?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:48","pubTimestamp":1777517308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B最高涨超23%，触及31.46港元创上市新高。值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54a3c0ad0e347d9e6f95c7a6e00c2a09","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","02493","BK0239","BK4585","688062","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557899","title":"迈威生物（688062）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557899?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:52","pubTimestamp":1777503142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年一季报。根据财报显示，迈威生物营收上升亏损收窄。截至本报告期末，公司营业总收入1.28亿元，同比上升184.89%，归母净利润-2.42亿元，同比上升17.07%。本次财报公布的各项数据指标表现尚佳。持有迈威生物最多的基金为易方达医药生物股票A，目前规模为19.96亿元，最新净值0.8025，较上一交易日下跌0.86%，近一年上涨13.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630025983","title":"迈威生物2026年第一季度净亏损2.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630025983","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630025983?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:24","pubTimestamp":1777379083,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩宋雨盈）4月28日，迈威生物发布2026年第一季度报告，报告期内，公司实现营业收入1.28亿元，同比增长184.89%；归属于上市公司股东的净亏损为2.42亿元，上年同期为亏损2.92亿元；归属于上市公司股东的扣除非经常性损益的净亏损为2.42亿元，上年同期为亏损2.93亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722717414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722717414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102446045","title":"深港通下的港股通标的证券名单调入迈威生物-B，今日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1102446045","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102446045?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:43","pubTimestamp":1777337012,"startTime":"0","endTime":"0","summary":"深交所公告，港股通标的证券名单发生调整并自2026年04月28日起生效，调入迈威生物-B。","market":"us","thumbnail":"https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07bac0175d858e54df48541d68aa044c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031601","title":"【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031601","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630031601?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:03","pubTimestamp":1777309406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 迈威生物-Ｂ 刊发全球发售配发结果公告，最终发售价厘定为每股27.64港元，股份将于2026年4月28日于港交所主板挂牌上市，每手买卖单位为200股。本次全球发售合共4713.02万股H股，其中香港公开发售4,713,200股，占全球发售10%；国际发售42,417,000股，占比90%。香港公开发售获大幅超额认购，有效申请126,378份，认购倍数约481.71倍，一手中签率为1.00%。国际发售获适度超额认购，认购倍数约3.46倍，承配人共82名。本次IPO未授出超额配售选择权。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","SPCX","02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394291","title":"上交所：将迈威生物-B(02493)调入沪港通下的港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630394291?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:09","pubTimestamp":1777295366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，上海证券交易所发布关于沪港通下港股通标的调整的通知。因上海证券交易所上市公司迈威生物(688062.SH)在香港联合交易所有限公司上市H股迈威生物-B(02493)，其H股不适用价格稳定期机制，且相应A股上市满10个交易日，根据《上海证券交易所沪港通业务实施办法》的有关规定，沪港通下港股通(以下简称港股通)标的名单发生调整，调入迈威生物-B(02493)，并自下一港股通交易日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02493","BK0239","BK4585","688062","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630801260","title":"每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801260?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:51","pubTimestamp":1777143068,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迈威生物报收于37.2元，较上周的38.77元下跌4.05%。本周关注点公司公告汇总：迈威生物H股发行价格区间为27.64港元至30.71港元，预计2026年4月28日挂牌上市。公司公告汇总迈威生物关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告迈威（上海）生物科技股份有限公司于2026年4月20日在香港联交所网站刊登H股招股说明书，并刊发H股发行价格区间为27.64港元至30.71港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780145813504,"stockEarnings":[{"period":"1week","weight":-0.0874},{"period":"1month","weight":-0.1176},{"period":"3month","weight":-0.1297},{"period":"6month","weight":-0.2947},{"period":"1year","weight":0.2423},{"period":"ytd","weight":-0.2098}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18977人(较上一季度增加2.21%)","perCapita":"10758股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"44673万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-U,688062,迈威生物-U股票,迈威生物-U股票老虎,迈威生物-U股票老虎国际,迈威生物-U行情,迈威生物-U股票行情,迈威生物-U股价,迈威生物-U股市,迈威生物-U股票价格,迈威生物-U股票交易,迈威生物-U股票购买,迈威生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}